Biocryst Pharmaceuticals (BCRX) Consolidated Net Income (2010 - 2026)

Biocryst Pharmaceuticals' Consolidated Net Income history runs 17 years deep, the most recent figure standing at -$721.8 million for Q1 2026.

• Quarterly Consolidated Net Income fell 2255762.5% year-over-year to -$721.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$458.0 million (down 756.52% YoY) and the FY2025 annual result came in at $263.9 million, up 396.87% from the prior year.
• Consolidated Net Income was -$721.8 million for Q1 2026 at Biocryst Pharmaceuticals, down from $245.8 million in the prior quarter.
• Across five years, Consolidated Net Income topped out at $245.8 million in Q4 2025 and bottomed at -$721.8 million in Q1 2026.
• A 5-year average of -$60.0 million and a median of -$36.1 million in 2023 frame the typical range for Consolidated Net Income.
• Annual changes were most pronounced in 2025 — Consolidated Net Income surged 1017.5% — and 2026, when it slumped 2255762.5%.
• Biocryst Pharmaceuticals' Consolidated Net Income stood at -$71.5 million in 2022, then gained by 13.71% to -$61.7 million in 2023, then jumped by 56.59% to -$26.8 million in 2024, then jumped by 1017.5% to $245.8 million in 2025, then sank by 393.6% to -$721.8 million in 2026.
• Business Quant data shows BCRX's Consolidated Net Income at -$721.8 million in Q1 2026, $245.8 million in Q4 2025, and $12.9 million in Q3 2025.